Nd:YAG laser treatment of recurrent epistaxis in hereditary hemorrhagic telangiectasia

Journal of Otolaryngology

Volumn 26, Issue 6, 1997, Pages 384-386

  Velegrakis, George A ^a,b   Prokopakis, Emmanuel P ^a   Papadakis, Chariton E ^a   Helidonis, Emmanuel S ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b NONE   (Greece)

Author keywords

Epistaxis; Heredity hemorrhagic telangiectasia; Nd:YAG laser; Rendu Osler Weber syndrome

Indexed keywords

CYCLOCAPROIC ACID; ESTROGEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARGON LASER; ARTERY EMBOLISM; ARTICLE; BLEEDING; CARBON DIOXIDE LASER; CLINICAL ARTICLE; CLINICAL TRIAL; ELECTROCOAGULATION; EPISTAXIS; GENE MUTATION; HEMOSTASIS; HUMAN; LASER COAGULATION; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; TELANGIECTASIA; TREATMENT OUTCOME; YAG LASER;

EID: 0031425695     PISSN: 03816605     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Haitjema T, Balder W, Disch SJM, et al. Epistaxis in hereditary hemorrhagic telangiectasia. Rhinology 1996; 34:176-178.
2. McAlister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary hemorrhagic telangiectasia type 1. Nat Genet 1994; 8:345-351.
3. Heutink P, Haitjema T, Breedveld GJ, et al. Linkage of hereditary hemorrhagic telangiectasia to chromosome 9q34 and evidence for locus heterogeneity. J Med Genet 1994; 31: 933-936.
4. De Santo LW. Hereditary hemorrhagic telangiectasia: Rendu-Osler-Weber syndrome. Minn Med 1967; 50:233-237.
5. Saunders WH. Septal dermoplasty for control of nose-bleeds caused by hereditary hemorrhagic telangiectasia or septal perforations. Trans Am Acad Ophthalmol Otolaryngol 1960; 64:500-506.
6. Saunders WH. Septal dermoplasty. Ten years experience. Am Acad Ophthalmol Otolaryngol 1968; 723:153-160.
7. Saunders WH. Septal dermoplasty. Its several uses. Laryngoscope 1970; 80:1342-1346.
8. Siniluoto TM, Leinonen AS, Kartunen AI, et al. Embolization for treatment of posterior epistaxis. An analysis of 31 cases. Arch Otolaryngol Head Neck Surg 1993; 119:837-841.
9. Deitmer T, Schurer G. Angiographische embolization als alternative zur Unterbindung der arteria maxillaris beim nasenbluten. Laryngol Otol Rhinol 1993; 72:379-382.
10. Flessa HC, Glueck HL. Hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease): management of epistaxis in nine patients using systemic hormone therapy. Arch Otolaryngol 1977; 103:148-151.
11. Harrison DF. Use of estrogen in treatment of familiar hemorrhagic telangiectasia. Laryngoscope 1982; 92:314-320.
12. Kluger PB, Sharplay SM, Hybels RL, et al. Nd:YAG laser. Intranasal photocoagulation in hereditary hemorrhagic telangiectasia. An update report. Laryngoscope 1987; 97: 1397-1401.
13. Werner JA, Rudert H. Einsatz des Nd:YAG Lasers in der Hals-, Nasen, Ohrenheilkunde. HNO 1992; 40:248-258.
14. Assar OS, Friedman CM, White RI. The natural history of epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 1991; 101:977-980.
15. Shaw CB, Wax MK, Wetmore SJ. Epistaxis: a comparison of treatment. Otolaryngol Head Neck Surg 1993; 109:60-65.
16. Phillips MD. Stopping bleeding in hereditary telangiectasia. N Engl J Med 1994; 330:1822-1823.
17. Shapshay SM, Oliver B. Treatment of hereditary hemorrhagic telangiectasia by Nd:YAG laser photocoagulation. Laryngoscope 1984; 94:1554-1556.
18. Parkin JL, Dixon JA. Argon laser treatment of head and neck vascular lesions. Otolaryngol Head Neck Surg 1985; 93:221-226.
19. Ilium P, Bjering P. Hereditary hemorrhagic telangiectasia treated by laser surgery. Rhinology 1988; 119:837-849.
20. Haye R, Austad J. Hereditary hemorrhagic telangiectasia -argon laser. Rhinology 1991; 29:5-9.
21. Siegel BS, Keane WM, Atkins JP, et al. Control of epistaxis in patients with hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 1991; 105:675-679.
22. Solomon H, Goldman L, Henderson B, et al. Histopathology of the laser treatment of port-wine lesions. Biopsy studies of treated areas observed up to three years after laser impacts. J Invest Dermatol 1968; 50:141-146.